|
 |
Pharmaceutical Manufacturing and Packing Sourcer
|
| Larry Klimczyk of Blackbay addresses the need to encourage widespread adoption of RFID in the pharmaceutical industry
In 2006 there was considerable hype surrounding Pfizer’s intent to employ RFID in Viagra packaging. Now, in 2007, many others within the pharmaceutical industry are also poised to begin reaping the benefits of RFID. RFID has the potential to offer much more than the established technologies such as barcoding to the pharmaceutical industry. Although RFID promises significant bottom line benefits, take-up has been slower than predicted. New developments are leading to more widespread adoption, but it is still considered by many to lack the plug and play maturity that so many businesses have come to expect from their technology tools.
PROVEN BENEFITS
Although the comparative advantages of RFID over the barcode have been stated, barcoding’s chief advantage still stands: it is incredibly cheap to produce. However, RFID’s benefits are many and impressive: non-line-of-sight reading; the ability to read multiple tags at once; the ability to store information on the back of a tag; the ability to consolidate a lot of information in a very small physical space; the ability to combine this information with telemetry information, such as temperature; and the ability to read at distance. These are making some headway towards creating cost effective solutions for enterprise. Some of the key benefits projected for the pharmaceutical industry in particular are:
- The ability to identify drugs at the individual and container level
- Assurance that the ID on the bottle has not been forged or mislabelled
- Minimised line-of-sight requirements to read product information
- Remote tracking of product movement and location
- Increased potential for reducing clinical trial times by reducing errors and improving delivery accuracy
There has been much speculation over the advantages of adopting RFID. In fact, many early adopters claim that they are already seeing a return on their investment. RFID can address many specific engineering and technical issues, but there is no one-size-fits-all answer and all but the simplest solutions will require specific engineering. |
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
Azopharma Product Development Group, Inc
HOLLYWOOD, Fla. – Azopharma Product Development Group, Inc. (“Azopharma”) announced today the addition of innovative state-of-the-art equipment at its formulation and manufacturing division, ApiCross Drug Delivery Technologies in Hollywood, Florida. The most recent acquisition is the MG Futura Capsule Filler which delivers the latest in capsule filling technology. The company has also added a Bausch & Strobel Aseptic Filling Isolator, equipment that is ground-breaking in the powder filling process. These additions support our previously implemented XcelodoseTM powder micro-dosing system. With these technologies, Azopharma is able to provide its clients with all forms of the capsule filling process. The new equipment is part of Azopharma’s recent manufacturing expansion which includes 17 new manufacturing suites for GMP, cytotoxic and aseptic products...
More info >> |
|
 |
